Expert consensus on the medication catalog for drug-induced liver injury and rational drug use

LI Jianchun; CHEN Di; JIN Pengfei; National Center of; Geriatric Pharmacy Professional Committee of the China Medicine Education Association; Pharmacy Management and Pharmaceutical Innovation Branch of the Chinese Association of Geriatric Research; Pharmacy Management and Pharmacy Service Branch of the Chinese Geriatrics Society; Geriatric Pharmacy Professional Committee of the Beijing Pharmaceutical Association

doi:10.6039/j.issn.1001-0408.2026.03.01

您当前的位置：

首页 >

文章列表页 >

Expert consensus on the medication catalog for drug-induced liver injury and rational drug use

更新时间：2026-02-11

- Expert consensus on the medication catalog for drug-induced liver injury and rational drug use
- ZHONGGUO YAOFANG Vol. 37, Issue 3, Pages: 273-280(2026)
- 作者机构：
  
  1.北京医院药学部/国家老年医学中心/中国医学科学院老年医学研究院/北京市药物临床风险与个体化应用评价重点实验室（北京医院），北京　100730
  2.航天中心医院药剂科，北京　100049
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2026.03.01
  CLC： R969.3;R575
- Received：04 September 2025，
  
  Revised：2026-01-23，
  
  Accepted：23 January 2026，
  
  Published：15 February 2026
- 稿件说明：
移动端阅览
李健春,陈頔,金鹏飞,等.肝损伤药物目录及合理用药专家共识 [J].中国药房,2026,37(03):273-280.

LI Jianchun,CHEN Di,JIN Pengfei.Expert consensus on the medication catalog for drug-induced liver injury and rational drug use[J].ZHONGGUO YAOFANG,2026,37(03):273-280.
李健春,陈頔,金鹏飞,等.肝损伤药物目录及合理用药专家共识 [J].中国药房,2026,37(03):273-280. DOI： 10.6039/j.issn.1001-0408.2026.03.01.

LI Jianchun,CHEN Di,JIN Pengfei.Expert consensus on the medication catalog for drug-induced liver injury and rational drug use[J].ZHONGGUO YAOFANG,2026,37(03):273-280. DOI： 10.6039/j.issn.1001-0408.2026.03.01.

摘要

目的

系统性梳理导致药物性肝损伤（DILI）的药物及其相关信息，制定《肝损伤药物目录及合理用药专家共识》（下文简称《共识》），为临床合理用药提供参考。

方法

系统检索各文献数据库、指南检索网站和肝损伤专业网站等，提取所纳入文献和网站资源中导致DILI的药物并根据来源赋值——LiverTox A类药物计3分、B类药物计2分；Hepatox、指南来源药物各计2分；共识和综述来源药物各计1分。纳入LiverTox A、B类及其余来源中总得分≥4分的药物形成导致DILI的药物初始目录。通过3轮德尔菲法（包括问卷调查和讨论会）收集并整合由全国27个省份的45名医学、药学专家组成的多学科专家组的意见，修订后形成《共识》终稿。结果与

结论

本《共识》共纳入何首乌、麻黄等12种中药，胺碘酮、阿托伐他汀等151种西药及其合理用药信息。其中，中药的合理用药信息包括循证得分、基于发病机制的肝损伤分型、基于生物化学异常模式的肝损伤分型、临床表型、实验室检查表现、潜伏期、消退时间、应对措施8项；西药的合理用药信息在此基础上增加了肝功能监测、停药、禁忌、慎用、剂量调整、危险因素6项，共计14项。本《共识》对导致DILI的药物及其合理用药信息进行了系统性梳理，有助于增强临床对DILI的预防、识别和处理能力，降低肝损伤发生率，确保患者用药安全、有效。

Abstract

OBJECTIVE

To systematically sort out the drugs causing drug-induced liver injury （DILI） and their relevant information， and to develop the

Expert consensus on the medication catalog for drug-induced liver injury and rational drug use

（hereinafter referred to as the

Consensus

）， so as to provide a reference for rational clinical use.

METHODS

Systematic searches were conducted across various literature databases， guideline retrieval websites and professional liver injury websites. Drugs identified as causing DILI from the included literature and online resources were extracted and assigned scores based on source credibility： three points for LiverTox A-class drugs and two points for B-class drugs； two points for drugs from Hepatox and guidelines； and one point for drugs from consensus and related literature sources. Drugs classified as LiverTox category A/B or with total scores ≥4 were included in the preliminary list of DILI-causing drugs. Opinions were collected and integrated from a multidisciplinary expert panel comprising 45 medical and pharmaceutical experts from 27 provinces across China through three rounds of the Delphi method （including questionnaires and discussion sessions）， a

nd after revision， the final version of

Consensus

was formed.

RESULTS &

CONCLUSIONS

This

Consensus

included 12 traditional Chinese medicines （TCMs） such as Polygoni Multiflori Radix and Ephedrae Herba， 151 Western medicines including amiodarone and atorvastatin， along with rational use information. For TCM， eight rational use information were included： evidence-based score， liver injury classification based on pathogenesis， liver injury classification based on biochemical abnormality pattern， clinical phenotype， laboratory examination manifestations， latency period， recovery time， and management strategies. For Western medicines， six additional items were included based on the TCM， namely liver function monitoring， discontinuation， contraindications， cautions， dose adjustments， and risk factors， totaling 14 items. This

Consensus

systematically compiles DILI drugs and their rational use information， which will support clinicians in enhancing the prevention， identification， and management of DILI， reducing the incidence of liver injury， and ensuring patient medication safety and efficacy.

关键词

Keywords

references

马世武，刘成海，刘晓琰，等 . 中国药物性肝损伤诊治指南：2023年版 [J ] . 胃肠病学， 2023 ， 28 （ 7 ）： 397 - 431 .

SHEN T ， LIU Y X ， SHANG J ， et al . Incidence and etio- logy of drug-induced liver injury in Chinese mainland [J ] . Gastroenterology ， 2019 ， 156 （ 8 ）： 2230 - 2241.e11 .

BJÖRNSSON E S ， BERGMANN O M ， BJÖRNSSON H K ， et al . Incidence，presentation，and outcomes in patients with drug-induced liver injury in the general population of Iceland [J ] . Gastroenterology ， 2013 ， 144 （ 7 ）： 1419 - 1425 .

SUK K T ， KIM D J ， KIM C H ， et al . A prospective nationwide study of drug-induced liver injury in Korea [J ] . Am J Gastroenterol ， 2012 ， 107 （ 9 ）： 1380 - 1387 .

VEGA M ， VERMA M ， BESWICK D ， et al . The incidence of drug- and herbal and dietary supplement-induced liver injury：preliminary findings from gastroenterologist-based surveillance in the population of the state of Delaware [J ] . Drug Saf ， 2017 ， 40 （ 9 ）： 783 - 787 .

LOW E X S ， ZHENG Q S ， CHAN E ， et al . Drug induced liver injury：East versus West：a systematic review and meta-analysis [J ] . Clin Mol Hepatol ， 2020 ， 26 （ 2 ）： 142 - 154 .

European Association for the Study of the Liver . EASL clinical practice guidelines：drug-induced liver injury [J ] . J Hepatol ， 2019 ， 70 （ 6 ）： 1222 - 1261 .

ANDRADE R J ， CHALASANI N ， BJÖRNSSON E S ， et al . Drug-induced liver injury [J ] . Nat Rev Dis Primers ， 2019 ， 5 ： 58 .

YUAN L Y ， KAPLOWITZ N . Mechanisms of drug-induced liver injury [J ] . Clin Liver Dis ， 2013 ， 17 （ 4 ）： 507 - 518 .

BJÖRNSSON H K ， BJÖRNSSON E S . Drug-induced liver injury：pathogenesis，epidemiology，clinical features，and practical management [J ] . Eur J Intern Med ， 2022 ， 97 ： 26 - 31 .

BABAI S ， AUCLERT L ， LE-LOUËT H . Safety data and withdrawal of hepatotoxic drugs [J ] . Therapie ， 2021 ， 76 （ 6 ）： 715 - 723 .

National Institute of Diabetes and Digestive and Kidney Diseases . Clinical and research information on drug-induced liver injury [EB/OL ] . [ 2023-02-28 ] . https：//www.ncbi.nlm.nih.gov/books/NBK547852/ https://www.ncbi.nlm.nih.gov/books/NBK547852/ .

National Institute of Diabetes and Digestive and Kidney Diseases . Categorization of the likelihood of drug induced liver injury [EB/OL ] . （ 2019-05-04 ）[ 2023-02-28 ] . https：//www.ncbi.nlm.nih.gov/books/NBK548392/ https://www.ncbi.nlm.nih.gov/books/NBK548392/ .

ALLISON R ， GURAKA A ， SHAWA I T ， et al . Drug induced liver injury：a 2023 update [J ] . J Toxicol Environ Health Part B ， 2023 ， 26 （ 8 ）： 442 - 467 .

VILLANUEVA-PAZ M ， MORÁN L ， LÓPEZ-ALCÁNTARA N ， et al . Oxidative stress in drug-induced liver injury （DILI）：from mechanisms to biomarkers for use in clinical practice [J ] . Antioxidants ， 2021 ， 10 （ 3 ）： 390 .

TIMOR-LÓPEZ E ， TOLOSA L ， DONATO M T . Cell-based approaches for the mechanistic understanding of drug-induced cholestatic liver injury [J ] . Arch Toxicol ， 2025 ， 99 （ 6 ）： 2243 - 2260 .

LI M ， LUO Q ， TAO Y Y ， et al . Pharmacotherapies for drug-induced liver injury：a current literature review [J ] . Front Pharmacol ， 2022 ， 12 ： 806249 .

ANDRADE R J ， AITHAL G P ， DE BOER Y S ， et al . Nomenclature，diagnosis and management of drug-induced autoimmune-like hepatitis （DI-ALH）：an expert opinion meeting report [J ] . J Hepatol ， 2023 ， 79 （ 3 ）： 853 - 866 .

LEISE M D ， POTERUCHA J J ， TALWALKAR J A . Drug-induced liver injury [J ] . Mayo Clin Proc ， 2014 ， 89 （ 1 ）： 95 - 106 .

CIOMS . Drug-induced liver injury （DILI）：current status and future directions for drug development and the post-market setting [EB/OL ] .[ 2023-02-28 ] . https：//cioms.ch/wp-content/uploads/2020/06/CIOMS_DILI_Web_16Jun-2020.pdf https://cioms.ch/wp-content/uploads/2020/06/CIOMS_DILI_Web_16Jun-2020.pdf .

王春枝，斯琴 . 德尔菲法中的数据统计处理方法及其应用研究 [J ] . 内蒙古财经学院学报（综合版）， 2011 ， 9 （ 4 ）： 92 - 96 .

DEVARBHAVI H ， AITHAL G ， TREEPRASERTSUK S ， et al . Drug-induced liver injury：Asia Pacific Association of Study of Liver consensus guidelines [J ] . Hepatol Int ， 2021 ， 15 （ 2 ）： 258 - 282 .

ZHU J Q ， CHEN M J ， BORLAK J ， et al . The landscape of hepatobiliary adverse reactions across 53 herbal and dietary supplements reveals immune-mediated injury as a common cause of hepatitis [J ] . Arch Toxicol ， 2020 ， 94 （ 1 ）： 273 - 293 .

BYEON J H ， KIL J H ， AHN Y C ， et al . Systematic review of published data on herb induced liver injury [J ] . J Ethnopharmacol ， 2019 ， 233 ： 190 - 196 .

LEE W J ， KIM H W ， LEE H Y ， et al . Systematic review on herb-induced liver injury in Korea [J ] . Food Chem Toxicol ， 2015 ， 84 ： 47 - 54 .

CHALASANI N P ， MADDUR H ， RUSSO M W ， et al . ACG clinical guideline：diagnosis and management of idiosyncratic drug-induced liver injury [J ] . Am J Gastroenterol ， 2021 ， 116 （ 5 ）： 878 - 898 .

FONTANA R J ， LIOU I ， REUBEN A ， et al . AASLD practice guidance on drug，herbal，and dietary supplement-induced liver injury [J ] . Hepatology ， 2023 ， 77 （ 3 ）： 1036 - 1065 .

STINE J G ， CHALASANI N . Chronic liver injury induced by drugs：a systematic review [J ] . Liver Int ， 2015 ， 35 （ 11 ）： 2343 - 2353 .

KATAREY D ， VERMA S . Drug-induced liver injury [J ] . Clin Med ， 2016 ， 16 （ Suppl.6 ）： s104 - s109 .

CLINTON J W ， KIPARIZOSKA S ， AGGARWAL S ， et al . Drug-induced liver injury：highlights and controversies in the recent literature [J ] . Drug Saf ， 2021 ， 44 （ 11 ）： 1125 - 1149 .

梁子晗，李佳辉，程爽，等 . 何首乌致肝损伤的信号通路及其作用机制 [J ] . 临床肝胆病杂志， 2024 （ 3 ）： 626 - 632 .

GONG L P ， SHEN X H ， HUANG N N ， et al . Research progress on hepatotoxicity mechanism of Polygonum multi- florum and its main components [J ] . Toxicon ， 2024 ， 248 ： 108040 .

LI C P ， RAO T ， CHEN X P ， et al . HLA-B*35:01 allele is a potential biomarker for predicting Polygonum multiflorum -induced liver injury in humans [J ] . Hepato- logy ， 2019 ， 70 （ 1 ）： 346 - 357 .

谭康安，杨婉娜，邱源旺，等 . 何首乌致药物性肝损伤与其他药物性肝损伤患者临床特征的比较 [J ] . 中华肝脏病杂志， 2025 ， 33 （ 5 ）： 463 - 469 .

LIU Y ， WANG W P ， SUN M Y ， et al . Polygonum multiflorum-induced liver injury：clinical characteristics，risk factors，material basis，action mechanism and current challenges [J ] . Front Pharmacol ， 2019 ， 10 ： 1467 .

马宁辉，陈依，许陈思涵，等 . 何首乌相关肝损伤研究进展 [J ] . 中国中药杂志， 2020 ， 45 （ 15 ）： 3594 - 3602 .

中华中医药学会中成药分会，中华中医药学会肝胆病分会，中国药学会临床中药学专业委员会，等 . 何首乌安全用药指南 [J ] . 中国中药杂志， 2020 ， 45 （ 5 ）： 961 - 966 .

ZHOU L ， WU B ， BIAN Y ， et al . Hepatotoxicity asso- ciated with statins：a retrospective pharmacovigilance study based on the FAERS database [J ] . PLoS One ， 2025 ， 20 （ 7 ）： e0327500 .

AVERBUKH L D ， TURSHUDZHYAN A ， WU D C ， et al . Statin-induced liver injury patterns：a clinical review [J ] . J Clin Transl Hepatol ， 2022 ， 10 （ 3 ）： 543 - 552 .

江林双，陈茂伟 . 阿托伐他汀药物性肝损伤的临床特征分析 [J ] . 中国全科医学， 2024 ， 27 （ 30 ）： 3772 - 3775，3783 .

BJÖRNSSON E ， JACOBSEN E I ， KALAITZAKIS E . Hepatotoxicity associated with statins：reports of idiosyncratic liver injury post-marketing [J ] . J Hepatol ， 2012 ， 56 （ 2 ）： 374 - 380 .

MA M M ， XU Y Y ， SUN L H ， et al . Statin-associated liver dysfunction and muscle injury：epidemiology，mechanisms，and management strategies [J ] . Int J Gen Med ， 2024 ， 17 ： 2055 - 2063 .

National Institute of Diabetes and Digestive and Kidney Diseases . Clinical and research information on drug-induced liver injury . Atorvastatin[EB/OL ] . （ 2025-03-03 ）[ 2025-11-07 ] . https：//www.ncbi.nlm.nih.gov/books/NBK548236/ https://www.ncbi.nlm.nih.gov/books/NBK548236/ .

李智，魏栋，万梅绪，等 . 他汀类药物致药物性肝损伤的研究进展 [J ] . 药物评价研究， 2024 ， 47 （ 5 ）： 941 - 950 .

QU K K ， ZHANG C N ， DONG L X ， et al . Association of ABCB1 polymorphisms with lipid homeostasis and liver injury response to atorvastatin in the Chinese population [J ] . Can J Physiol Pharmacol ， 2020 ， 98 （ 1 ）： 15 - 22 .

张天栋，武德珍，李奎，等 . ABCB1（2677T＞G）、SLCO1B1（521T＞C）基因多态性与阿托伐他汀个体化用药的研究 [J ] . 中国医院药学杂志， 2018 ， 38 （ 23 ）： 2406 - 2409 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

某院2013－2015年替加环素使用安全性分析

医院药学信息化管理路径与效果评价

Analysis of the application status of prescription pre-review systems in Yunnan province

Expert consensus on pharmaceutical active consultation service in medical institutions

Related Author

SU Dan

XU Shan

WANG Junping

WANG Zuojun

CHE Yunxiu

WEI Ping

ZHANG Jingyi

XU Fan

Related Institution

Wuhua Campus， the 920th Hospital of Joint Logistics Support Force of PLA

Yunnan Pharmaceutical Association

Dept. of Pharmacy， Yan’an Hospital Affiliated to Kunming Medical University

Dept. of Pharmacy， the Second Affiliated Hospital of Kunming Medical University

Dept. of Pharmacy， Zhaotong First People’s Hospital

⁰